SEQUILLA CARTER: Open Payments
NPI 1518476647 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$777 in 20 payments from 6 companies in 2025. Trend: 2023 $531 · 2024 $740 · 2025 $777
Food & beverage: $777
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 4 | $208 |
| Neurocrine BioSciences, Inc. | 6 | $177 |
| ABBVIE INC. | 5 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $162 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
Products named: Auvelity, INGREZZA, VRAYLAR, CAPLYTA, REXULTI, SPRAVATO.
Industry payments across CT — which companies pay providers there.
